Properties (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availableIn |
various dosages
|
| gptkbp:brand |
gptkb:NexGard_Spectra
gptkb:NexGard_Chewables |
| gptkbp:chemicalFormula |
C16H14ClF3N2O2S
|
| gptkbp:class |
isoxazoline
|
| gptkbp:clinicalTrials |
studied for efficacy against fleas
studied for efficacy against ticks studied for long-term effects studied for safety in dogs |
| gptkbp:contraindication |
anorexia in rare cases
dogs less than 8 weeks old dogs weighing less than 2 kg increased thirst in rare cases increased urination in rare cases seizures in rare cases skin reactions in rare cases hypersensitivity_to_afoxolaner |
| gptkbp:developedBy |
gptkb:Merck_&_Co.
|
| gptkbp:dissolved |
soluble in organic solvents
|
| gptkbp:dosageForm |
chewable tablet
|
| gptkbp:duration |
30 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
afoxolaner
|
| gptkbp:interactsWith |
may interact with other medications
|
| gptkbp:issuedBy |
oral tablet
|
| gptkbp:lastProduced |
2013
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States gptkb:NexGard |
| gptkbp:packaging |
blister pack
|
| gptkbp:patentStatus |
patented
expires in 2024 |
| gptkbp:regulatoryCompliance |
received in multiple countries
|
| gptkbp:researchAreas |
ongoing studies for other parasites
|
| gptkbp:safetyFeatures |
generally safe for use in dogs
not recommended for breeding dogs not recommended for pregnant dogs |
| gptkbp:sideEffect |
vomiting
diarrhea lethargy |
| gptkbp:storage |
store at room temperature
|
| gptkbp:targets |
dogs
cats |
| gptkbp:triggerType |
inhibits_GABA_and_glutamate-gated_chloride_channels
|
| gptkbp:usedFor |
treating fleas
treating ticks |
| gptkbp:weight |
388.80 g/mol
|